Living With T1D/July 30, 2026/2 min read

GLP-1 Medications in Type 1 Diabetes: What Adults Need to Know About Safe Use

A new clinical guide outlines how certain GLP-1 receptor agonist medications can be used safely alongside insulin in adults with Type 1 diabetes. Here's what the evidence shows about who might benefit and how to use them responsibly.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dmental healthtechnologysupport

Key takeaways

GLP-1 receptor agonists (medications like semaglutide and dulaglutide) can be used as add-on therapy with insulin in Type 1 diabetes, but they are not a replacement for insulin
Not all adults with Type 1 diabetes are candidates for these medications—specific patient profiles are more likely to benefit
Careful patient education, monitoring, and insulin dose adjustments are essential to use these medications safely
Proper counseling and a structured implementation plan help prevent side effects and ensure better outcomes

What Are GLP-1 Receptor Agonists and How Do They Fit Into Type 1 Diabetes Care?

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications originally developed to help people with Type 2 diabetes manage blood sugar and weight. In recent years, researchers and clinicians have explored whether these medications might also help some adults with Type 1 diabetes when used alongside insulin therapy.

A new clinical guidance document, published in Endocrinology and Metabolism Clinics of North America, provides detailed recommendations for when and how to safely use GLP-1RAs as an add-on treatment in Type 1 diabetes. The guidance emphasizes that these medications work best as part of a comprehensive treatment plan, not as standalone therapy.

Who Might Benefit from GLP-1 Medications?

Not every adult with Type 1 diabetes is a candidate for GLP-1 receptor agonists. The new clinical guidance identifies specific patient phenotypes—distinct characteristic patterns—most likely to benefit from these medications.

If you're considering whether a GLP-1RA might be appropriate for you, your healthcare team will evaluate your individual situation to determine if you fit the profile of someone who may respond well to this type of add-on therapy.

Getting Started Safely: Patient Education and Monitoring

Starting a GLP-1RA requires more than simply adding a new prescription. The clinical guidance emphasizes that patients need comprehensive education before and during treatment. This includes understanding how the medication works, what side effects to watch for, and how it may interact with insulin dosing.

Monitoring is equally important. Your healthcare team will track your response to the medication and make adjustments over time. This might include regular check-ins to assess how you're tolerating the medication and whether your insulin doses need to be changed.

The guidance also outlines strategies to manage common side effects and provides a framework for adjusting insulin doses in an individualized way. This personalized approach helps ensure you're getting the maximum benefit while minimizing unwanted effects.

A Practical Tool for Healthcare Providers

To support safe implementation of GLP-1RAs in clinical practice, the guidance includes a provider-facing checklist. This one-page tool helps doctors and diabetes care teams ensure they're following best practices when prescribing these medications to adults with Type 1 diabetes.

The checklist brings together the key steps—from identifying suitable candidates to counseling patients properly to monitoring outcomes—into a single, actionable format designed for real-world clinical care.

Evidence label

Source: Endocrinology and metabolism clinics of North America. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.